203 related articles for article (PubMed ID: 25017433)
1. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.
Treharne C; Liu FX; Arici M; Crowe L; Farooqui U
Appl Health Econ Health Policy; 2014 Aug; 12(4):409-20. PubMed ID: 25017433
[TBL] [Abstract][Full Text] [Related]
2. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
5. The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.
Liu FX; Treharne C; Culleton B; Crowe L; Arici M
BMC Nephrol; 2014 Oct; 15():161. PubMed ID: 25278356
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis for Thai Patients With End-Stage Renal Disease.
Thaweethamcharoen T; Sritippayawan S; Noparatayaporn P; Aiyasanon N
Value Health Reg Issues; 2020 May; 21():181-187. PubMed ID: 32044691
[TBL] [Abstract][Full Text] [Related]
7. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
Surendra NK; Abdul Manaf MR; Hooi LS; Bavanandan S; Mohamad Nor FS; Firdaus Khan SS; Meng OL; Abdul Gafor AH
PLoS One; 2019; 14(10):e0218422. PubMed ID: 31644577
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?
Yousefi M; Rezaei S; Hajebrahimi S; Falsafi N; Keshvari-Shad F
BMC Nephrol; 2024 Mar; 25(1):85. PubMed ID: 38448887
[TBL] [Abstract][Full Text] [Related]
9. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
10. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
12. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
De Vecchi AF; Dratwa M; Wiedemann ME
Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
[TBL] [Abstract][Full Text] [Related]
13. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of extended time on peritoneal dialysis as a result of using polyglucose: the application of a Markov chain model to forecast changes in the development of the ESRD programme over time.
Weijnen TJ; van Hamersvelt HW; Just PM; Struijk DG; Tjandra YI; ter Wee PM; de Charro FT
Nephrol Dial Transplant; 2003 Feb; 18(2):390-6. PubMed ID: 12543897
[TBL] [Abstract][Full Text] [Related]
15. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
[TBL] [Abstract][Full Text] [Related]
16. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact Analysis of the Change in Peritoneal Dialysis Use Rate in Korea.
Kim J; Lee NR; Son SK; Lee JP; Park JT; Kim YJ; Ryu DR
Perit Dial Int; 2019; 39(6):547-552. PubMed ID: 31337696
[No Abstract] [Full Text] [Related]
18. Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis.
Sennfält K; Magnusson M; Carlsson P
Perit Dial Int; 2002; 22(1):39-47. PubMed ID: 11929142
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
20. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]